The study was aimed at evaluating oxaliplatin/doxorubicin combination therapy in recurrent ovarian cancer. Patients with recurrent ovarian cancer in whom the platinum-free interval had been < 24 months received doxorubicin/oxaliplatin. The median progression-free survival times in platinum-sensitive and platinum-resistant cancer were 10.8 and 6.7 months, respectively. The combination of oxaliplatin/doxorubicin is an active regimen in both platinum-sensitive and platinum-resistant ovarian cancer.
Beth Cronin, Katina Robison, Christina Raker, Richard Moore, Cornelius O. Granai, Don S. Dizon Pegylated liposomal doxorubicin (PLD) has been effective in recurrent ovarian cancer, but the ideal treatment length is unknown. In this retrospective chart review, we examined whether prolonged treatment increased progression-free (PFS) or overall survival (OS). Our data suggest that PLD treatment to progression is associated with a PFS advantage compared with treatment to best response (15 vs. 10 months).
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Outcomes Determining the optimal time interval between debulking surgery to adjuvant chemotherapy is crucial in minimizing morbidity among ovarian cancer patients. A total of 43 operable ovarian cancer cases were analyzed comparing between 2-week and 6-week interval. There were no significant different in short term morbidity between the groups. However the 2-week interval group had a better CA-125 reduction. We analyzed the effect of the N factor on prognosis of T3C ovarian cancer patients who underwent optimal surgery (OpS). According to the analyses of N factor in OpS group, prognosis was poor in N1 group, however prognosis was significantly better in the complete group than in the other group with residual tumor of less than 1 cm.
Survival Outcomes of Clinical Trials in Patients With Recurrent Cervical Cancer
Christa I. Nagel, William N. Denson, Debra L. Richardson, Siobhan M. Kehoe, David S. Miller, Jayanthi S. Lea A large proportion of cervical cancer patients have a lower socioeconomic background and barriers to clinical trial participation. We hypothesized that patients participating in a clinical trial would have better outcomes compared to those not enrolled in a trial. This was a retrospective cohort study of women treated for recurrent cervical cancer on versus off clinical trial. We found that the progression free and overall survival between women treated with chemotherapy on or off trial for cervical cancer survival is similar. Concurrent chemo-radiation forms the standard of care in majority of carcinoma cervix and radiation proctitis is one of the commonly encountered side-effect. In this study we analysed sixty six patients of carcinoma cervix treated with radiation therapy and observed an increased incidence of radiation proctitis in patients treated using conformal radiotherapy as opposed to conventional therapy. 
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